The most common reason a man in his fifties hesitates before starting testosterone is not the needles, the cost, or what his wife will think. It is the prostate. Some version of this question comes across my desk almost every week: "Isn't testosterone going to feed prostate cancer?" He usually heard it from a friend, a forum thread, or a primary care visit years ago, and he has carried it as settled fact ever since. It is the single fear that stops the most otherwise-good candidates from getting treated.
It is a fair question, and it deserves a real answer instead of a reassuring wave of the hand. The honest version is more nuanced than either "testosterone is dangerous for the prostate" or "testosterone is totally safe, don't worry about it." What follows is how I actually talk this through with men considering hormone therapy for men: where the fear came from, what the modern evidence shows, what a normal PSA response looks like, and what responsible monitoring involves. This is the prostate companion to my piece on testosterone and heart health — the two fears that stall the most men, answered the same honest way.
Where the "fuel on the fire" idea came from
The concern is not something patients invented. It has real historical roots. In the 1940s, work on advanced prostate cancer established that lowering a man's testosterone — surgically or chemically — could cause an advanced, hormone-sensitive prostate cancer to regress, sometimes dramatically. That discovery was genuinely important. It is the basis for androgen-deprivation therapy, which remains a mainstay of treatment for advanced prostate cancer to this day.
The trouble is the inference that followed. The reasoning went: if taking testosterone away shrinks prostate cancer, then adding testosterone must grow it — and, by extension, must cause it in the first place. That leap felt intuitive, and it hardened into decades of blanket caution. Every man asking about testosterone got filed next to the man with metastatic disease.
But look closely at where the original observation came from. It came from men who already had advanced, established, hormone-sensitive prostate cancer, and from a relatively small number of patients. It told us something real about how an existing advanced cancer behaves when you manipulate hormones. It told us very little about whether restoring a deficient middle-aged man to a normal range causes a cancer to appear in the first place. Those are different questions, and for a long time the field answered the second one using evidence that only spoke to the first.
The saturation model — why the old fear did not hold up
The more useful framework for understanding the prostate's relationship with testosterone is what researchers have called the saturation model. The idea, stated plainly: the androgen receptors in prostate tissue appear to become saturated at relatively low testosterone concentrations. Once those receptors are full, adding more testosterone does not produce proportionally more prostate stimulation. It is a little like watering a plant that has already absorbed all the water it can hold — pouring on more does not make it grow faster.
This model helps explain a repeated real-world observation: raising a man's testosterone from deficient up to a normal physiological range does not reliably drive PSA up the way the old "more testosterone equals more prostate growth" idea predicted. If the prostate's receptors are already saturated across most of the normal range, then moving a man from low to normal is not adding much signal the prostate can even respond to.
I want to be careful here, because the saturation model is a framework, not the final word. It does not mean testosterone is irrelevant to the prostate, and it does not mean anything goes. It means the simple, linear, dose-makes-cancer story that scared a generation of men does not match how the tissue actually behaves. That is a meaningful correction, and it lines up with what the larger trials have found.
What the TRAVERSE trial found about the prostate
The strongest recent evidence comes from the TRAVERSE trial — a large, randomized, placebo-controlled study designed primarily to answer the cardiovascular safety question in men with low testosterone. Because it followed thousands of hypogonadal men on testosterone versus placebo, it was also positioned to track prostate outcomes carefully.
The direction of the prostate findings was reassuring. In the men treated with testosterone, the trial did not show a meaningful increase in prostate cancer — including high-grade, more aggressive prostate cancer — compared with the men on placebo. I am describing the direction of the result rather than throwing numbers at you, because the point is the pattern: a study built to catch a safety signal did not find the prostate catastrophe the old model predicted.
The honest caveats matter too. The men in the trial were screened at entry, so those with known or suspected prostate cancer were not enrolled — which is exactly how testosterone therapy should be approached in practice anyway. The follow-up window is finite, and no single trial closes a question forever. But TRAVERSE points the same direction as the saturation model and the meta-analyses that came before it, and together they represent the best evidence we currently have. For the parallel story on the cardiovascular side of that same trial, my heart-health piece walks through it in detail.
What a normal PSA response to starting testosterone looks like
Patients often expect that starting testosterone will send their PSA on some alarming upward trajectory. That is not the usual pattern. When a genuinely low man is restored toward a normal range, a small early rise in PSA can occur over the first several months as prostate tissue responds to a normalized androgen level. Then it typically plateaus. That early, modest bump is expected physiology, not a warning sign.
What actually gets my attention is a different shape to the curve. A rapid rise. A value that keeps climbing past the initial adjustment period instead of settling. A confirmed jump above an age-appropriate threshold on repeat testing. A change paired with an abnormal prostate exam. Any of those patterns triggers a pause and a conversation with urology — not a quiet dose adjustment and a hope that it settles.
It is also worth saying that PSA is an imperfect marker on its own. It moves with prostate infection, with recent ejaculation, with vigorous cycling, and with ordinary benign enlargement. A single elevated number is interpreted in context, ideally confirmed on a repeat draw under clean conditions, before anyone panics or makes a decision. Reading one PSA value in isolation is how good men get scared out of treatment they would have benefited from, and it is also how a real problem gets waved away. Context is the whole game.
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Bring your labs, including a recent PSA if you have one, and we will read the whole picture together.
A typical monitoring rhythm
When men ask how the prostate gets watched during treatment, I describe it as a rhythm rather than a rigid schedule. Before starting, we establish a baseline PSA and talk through prostate exam and family history. In the first several months, once levels are stabilizing, there is an early recheck. After that, prostate monitoring folds into the same periodic follow-up labs we already run for anyone on testosterone therapy — it is not a separate ordeal.
This is the same monitoring discipline that makes any hormone therapy responsible: you do not start a man and then disappear. The comprehensive hormone panel I run already includes PSA for age-appropriate men alongside the hormone and metabolic markers, and the three-month reassessment is where a lot of this gets reviewed with the data in front of both of us. If you want to see exactly what belongs on that lab work, I have written separately about what a comprehensive hormone panel should include.
The cadence itself is individualized. A 45-year-old with a low baseline PSA and no family history gets watched on a lighter schedule than a 62-year-old with a father and brother who had prostate cancer. The principle is constant — screen before, watch during, keep a low threshold to involve urology — but the specifics bend to the man in front of me.
Benign enlargement is a separate question from cancer
A lot of the prostate anxiety men bring in actually blends two different concerns that deserve to be pulled apart. One is cancer risk. The other is urinary symptoms from benign prostatic enlargement — a weaker stream, more urgency, getting up at night to urinate. These are not the same problem, and testosterone's relationship to each is different.
Many midlife men have some degree of benign enlargement, and they often assume testosterone will make the plumbing worse. The evidence here is reassuring but appropriately hedged: for most men, testosterone therapy has not been shown to meaningfully worsen urinary symptoms, and plenty of those symptoms are not primarily hormonal to begin with. If a man already has significant obstructive symptoms, that is worth evaluating on its own track rather than blaming or crediting testosterone for it. Waking repeatedly overnight has several possible drivers worth sorting out, and lumping it in with cancer fear does not help anyone.
The takeaway I want men to hold onto: an enlarged prostate is a comfort-and-flow issue to manage, not automatically a cancer issue to fear, and neither one is a reason to reflexively rule out treatment.
When a prostate-cancer history changes everything
Here is the carve-out, and it is not a footnote. Everything I have said so far applies to men without a personal history of prostate cancer. A man who has been treated for prostate cancer, or who is under active surveillance for it, is a fundamentally different conversation.
For that man, any testosterone decision belongs with his urologist and, where relevant, his oncologist — co-managing it together, not a wellness clinic deciding on its own. The field has grown more nuanced here in recent years; some men with treated, low-risk disease are considered for testosterone under close specialist supervision, because the blanket "never" of the old era was itself built on the same overreaching inference I described at the top. But "more nuanced under a specialist's care" is worlds apart from "go ahead, it's fine." I have written more on reading hormone therapy and cancer risk honestly, and the short version is this: if you carry that history, I co-manage with your cancer team, or I do not proceed. That boundary protects you, and I hold it without apology.
How I actually handle the prostate conversation in clinic
In practice, the prostate is neither something I ignore nor something I let fear a good candidate out of treatment. I screen before I start. That means a baseline PSA, an honest family history, and an exam or referral where age and risk factors call for it. I will not begin testosterone injection therapy, a Biote pellet therapy schedule, or any other route on a man with an unevaluated abnormal PSA or a suspicious exam — that gets worked up first, full stop. As I have written in my longer piece on how I run a men's testosterone workup, active prostate cancer is one of the clear reasons I tell a man no.
What I am doing, really, is treating the prostate as something we watch together — not something we pretend away, and not something we let block a treatment that could genuinely change how a man feels and functions. Men in their forties who have been told their testosterone is "normal" while they feel anything but, and men who have never had anyone actually explain the difference between total and free testosterone, deserve a prostate conversation that is honest in both directions: honest about the reassurance the evidence provides, and honest about the monitoring the reassurance is built on.
The honest bottom line
So, does testosterone cause prostate cancer? The best current evidence says that restoring a deficient man to a normal physiological range does not appear to cause prostate cancer, and that the old "fuel on the fire" model came from a very different clinical situation than the one most of my patients are in. The saturation model explains why, and TRAVERSE is the strongest data we have pointing the same direction.
That is not the same as "no monitoring required." It means the responsible path is screening before you start, watching during treatment, and keeping a low threshold to bring in urology if the pattern ever looks off. A prostate-cancer history is its own conversation with its own specialists. Everything else is a manageable, monitorable part of good care.
If you are a man in Columbus, Warner Robins, or anywhere across middle Georgia who has been holding off on treatment because of the prostate question, the concrete next step is to bring your labs — including a recent PSA if you have one — to a consultation. The Start Here pathway will route you to the right starting point, and we will read the whole picture together before anyone decides anything.
This article is educational and is not a substitute for an evaluation with a qualified clinician. Prostate screening and testosterone decisions are individual, and a personal history of prostate cancer requires the involvement of your urology and oncology team.
Medical disclaimer: This article is educational and does not constitute medical advice or a treatment recommendation. Testosterone therapy decisions, PSA interpretation, and prostate screening require individualized evaluation by a qualified clinician, and a personal history of prostate cancer requires urology and oncology involvement. Nothing here should replace that care.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.